A. Macleod

H. Schwartz, J. Cates, T. Yoshii, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates

A. Gruber, S. Hanson, B. Monia, 2013, Arteriosclerosis, thrombosis, and vascular biology.

Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

M. D. De Velasco, K. Nishio, B. Davies, 2019, JCI insight.

Preclinical Development Transcription Factor Stat 5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo

M. Gleave, A. Zoubeidi, L. Fazli, 2011 .

Antisense: Progress Towards Gene-Directed Cancer Therapy

S. Crooke, A. Macleod, 2002 .

Results Inhibition of FXI With aXIMab : Effects on Thrombosis in the Baboon Model

A. Gruber, S. Hanson, B. Monia, 2013 .

Inhibition d'histone deacetylase

A. Macleod, Zuomei Li, J. Besterman, 2000 .

oligonucleotide in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

J. Nemunaitis, R. Kurzrock, M. Jo, 2018 .

Biological Study of MG 98 , an Oligodeoxynucleotide Antisense to DNAMethyltransferase 1 , in Patients with High-RiskMyelodysplasia andAcuteMyeloid Leukemia

J. Byrd, W. Stock, Shujun Liu, 2008 .

A novel and translational role for autophagy in antisense oligonucleotide trafficking and activity

Shuling Guo, J. Matson, A. Macleod, 2019, Nucleic acids research.

Antisense oligonucleotide targeting of thrombopoietin represents a novel platelet depletion method to assess the immunomodulatory role of platelets

J. Berger, Tessa J. Barrett, L. Segal, 2020, Journal of thrombosis and haemostasis : JTH.

Reversing Antisense Oligonucleotide Activity with a Sense Oligonucleotide Antidote: Proof of Concept Targeting Prothrombin.

Shuling Guo, B. Monia, A. Macleod, 2015, Nucleic acid therapeutics.

Abstract ND11: The discovery and characterization of ION-537: A next generation antisense oligonucleotide inhibitor of YAP1 in preclinical cancer models

A. Macleod, 2021, Experimental and Molecular Therapeutics.

Kininogen supports inflammation and bacterial spreading during Streptococccus Pyogenes Sepsis

S. Mikkat, B. Kreikemeyer, D. Koczan, 2020, EBioMedicine.

Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups.

A. Macleod, S. Raeppel, F. Gaudette, 2010, Bioorganic & medicinal chemistry letters.

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

M. Robert, A. Macleod, A. Vaisburg, 2008, Bioorganic & medicinal chemistry letters.

Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.

E. Borden, S. I. Bae, D. Lindner, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Noncoding RNA MALAT 1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells

D. Spector, S. Diederichs, Tony Gutschner, 2013 .

Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.

Tianyuan Zhou, Youngsoo Kim, A. Macleod, 2016, Methods in molecular biology.

Molecular and Cellular Pathobiology The Noncoding RNA MALAT 1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells

D. Spector, S. Diederichs, Tony Gutschner, 2013 .

Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.

B. Monia, C. May, A. Macleod, 2011, Blood.

DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells

M. Robert, A. Macleod, I. Chute, 2003, Nature Genetics.

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly.

E. Eisenhauer, R. Donehower, A. Macleod, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

DNA Methyltransferase Inhibitors

A. Macleod, G. Reid, 2005 .

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

C. Collins, M. Gleave, A. Wyatt, 2015, Clinical Cancer Research.

Down-regulation of Human DNA-(Cytosine-5) Methyltransferase Induces Cell Cycle Regulators p16 ink4A and p21WAF/Cip1 by Distinct Mechanisms*

A. Macleod, M. Fournel, J. Besterman, 1999, The Journal of Biological Chemistry.

Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice.

S. Strickland, A. Macleod, P. Singh, 2017, Blood.

Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.

M. Ziol, J. Zucman‐Rossi, V. Paradis, 2020, Journal of hepatology.

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

P. Lyne, B. Monia, D. Blakey, 2017, Science Translational Medicine.

Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo

M. Gleave, A. Zoubeidi, L. Fazli, 2011, Molecular Cancer Therapeutics.

Antisense oligonucleotide activity in tumour cells is influenced by intracellular LBPA distribution and extracellular vesicle recycling

Paul R. J. Davey, E. Chiarparin, N. Rustogi, 2021, Communications Biology.

N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.

A. Macleod, Nancy Z. Zhou, S. Raeppel, 2009, Bioorganic & medicinal chemistry letters.

Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.

A. Kalita, A. Macleod, S. Leit, 2002, Cancer research.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

J. Nemunaitis, R. Kurzrock, M. Jo, 2018, Journal of Immunotherapy for Cancer.

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer

S. Barry, G. Kar, P. Lyne, 2022, Journal for ImmunoTherapy of Cancer.

(2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors

A. Kalita, A. Macleod, O. Moradei, 2004 .

The Androgen Receptor: A Therapeutic Target in Desmoplastic Small Round Cell Sarcoma

P. A. Futreal, Hannah C. Beird, A. Lazar, 2022, bioRxiv.

Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.

A. Chinnaiyan, Xuhong Cao, Xiaoju Wang, 2018, Cancer research.

IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production

B. Monia, B. Baker, A. Macleod, 2019, Nucleic acid therapeutics.

Inhibition of Prekallikrein for Hereditary Angioedema.

J. Bernstein, W. Lumry, B. Baker, 2022, The New England journal of medicine.

Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.

B. Monia, C. May, A. Macleod, 2013, Nucleic acid therapeutics.

Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.

Chun-Peng Liao, M. Gross, Youngsoo Kim, 2017, Endocrine-related cancer.

Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.

E. Borden, S. I. Bae, D. Leaman, 2006, Cancer research.

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models

M. Jo, Tianyuan Zhou, Youngsoo Kim, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer’s disease

S. Strickland, A. Macleod, A. Revenko, 2018, Proceedings of the National Academy of Sciences.

Antisense therapies for cancer: Bridging the pharmacogenomic divide

A. Macleod, 2013 .

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Isabelle Paquin, Daniel Delorme, A. Kalita, 2008, Journal of medicinal chemistry.

Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.

Dipali Sharma, Xiaowei Yang, N. Davidson, 2005, Molecular endocrinology.

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

S. Steinberg, M. Raffeld, E. Levy, 2016, International journal of cancer.

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma

L. Hazlehurst, J. Gemmer, A. Macleod, 2016, Oncogene.

(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.

A. Kalita, A. Macleod, O. Moradei, 2004, Bioorganic & medicinal chemistry letters.

Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment.

A. Macleod, J. Besterman, G. Reid, 2002, Current opinion in molecular therapeutics.

Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma

L. Ratner, J. Harding, Tianyuan Zhou, 2020, Retrovirology.

Identification of a novel series of potent RON receptor tyrosine kinase inhibitors.

C. Maroun, A. Macleod, S. Raeppel, 2010, Bioorganic & medicinal chemistry letters.

Abstract 5561: High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models

S. Barry, P. Lyne, A. Macleod, 2018, Clinical research.

LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma

Ying Wang, Liuqing Yang, Jaffer A. Ajani, 2019, Molecular Cancer.

SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes.

Nadine H. Elowe, A. Macleod, A. Vaisburg, 2009, Bioorganic & medicinal chemistry letters.

Identification and Partial Purification of Human Double Strand RNase Activity

A. Macleod, W. Lima, Hongjiang Wu, 1998, The Journal of Biological Chemistry.

An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma.

S. Morrison, H. Herschman, Tianyuan Zhou, 2019, Cancer research.

Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer ’ s disease mice Running title : FXII depletion ameliorates

S. Strickland, A. Macleod, P. Singh, 2017 .

Antisense Oligonucleotide Induces Synthetic Lethality in HK 1-HK 2 + Multiple Myeloma

S. Morrison, H. Herschman, Tianyuan Zhou, 2019 .

LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma

J. Ajani, Guangchun Han, Linghua Wang, 2019, Molecular Cancer.

Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats

A. Clermont, E. Feener, L. Pham, 2021, Translational Stroke Research.

Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.

A. Kalita, M. Robert, A. Macleod, 2008, Bioorganic & medicinal chemistry letters.

Abstract 4359: Characterization of GalNAc-conjugated generation 2.5 ASOs in DEN and DEN/CCL4-induced HCC tumors

M. Jo, Tianyuan Zhou, Youngsoo Kim, 2015 .

The Biological Roles of Post‐Synthetic Modifications of Basic Nuclear Proteins

M. Sung, B. M. Honda, E. Candido, 2008 .

The contact system proteases play disparate roles in streptococcal sepsis

S. Mikkat, D. Koczan, A. Macleod, 2019, Haematologica.

Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats

A. Clermont, E. Feener, L. Pham, 2021, Translational Stroke Research.

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

C. Collins, M. Gleave, A. Wyatt, 2015, Clinical Cancer Research.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

A. Kalita, M. Robert, A. Macleod, 2008, Molecular Cancer Therapeutics.